Skip to main content

RY

Stock

RY

Stock
Financials
Banks - Diversified

Performance overview

RY Price
Price Chart

Forward-looking statistics

Beta
0.50
Risk
15.61%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Royal Bank of Canada is a Canadian multinational financial services company and the largest bank in Canada by market capitalization. The bank serves over 17 million clients and has more than 89,000 employees worldwide.

Company info

SectorFinancials
IndustryBanks - Diversified
Employees94K
Market cap$150.4B

Fundamentals

Enterprise value-$78.3B
Revenue$42.7B
Revenue per employee—
Profit margin31.33%
Debt to equity2.71

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)$9.21
Dividend per share$4.13
Revenue per share$41.13
Avg trading volume (30 day)$125M
Avg trading volume (10 day)$112M
Put-call ratio—

Macro factor sensitivity

Growth-0.1
Credit+4.0
Liquidity+0.2
Inflation-2.5
Commodities-0.8
Interest Rates-0.9

Valuation

Dividend yield3.10%
PEG Ratio14.31
Price to sales3.22
P/E Ratio14.31
Enterprise Value to Revenue-1.83
Price to book1.53

Upcoming events

Next earnings dayMay 29, 2025
Next dividend day—
Ex. dividend dayJuly 24, 2025

News

Array Technologies, Inc. (ARRY) Suffers a Larger Drop Than the General Market: Key Insights

Array Technologies, Inc. (ARRY) reached $7.47 at the closing of the latest trading day, reflecting a -2.23% change compared to its last close.

Zacks Investment Research (July 11, 2025)
Tilray Brands, Inc. (TLRY) Declines More Than Market: Some Information for Investors

In the closing of the recent trading day, Tilray Brands, Inc. (TLRY) stood at $0.58, denoting a -8.88% move from the preceding trading day.

Zacks Investment Research (July 11, 2025)
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up

Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.

Zacks Investment Research (July 10, 2025)
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data

Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.

Zacks Investment Research (July 10, 2025)
Best Value Stocks to Buy for July 10th

BAYRY, INSW and GOOS made it to the Zacks Rank #1 (Strong Buy) value stocks list on July 10, 2025.

Zacks Investment Research (July 10, 2025)
New Strong Buy Stocks for July 10th

ASTH, LGCY, STM, BAYRY and KD have been added to the Zacks Rank #1 (Strong Buy) List on July 10, 2025.

Zacks Investment Research (July 10, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free